外周血干细胞移植治疗糖尿病足的研究进展

Advances in Studies on Autologous PBSCT for Treating Diabetic Foot

近年来,糖尿病患病率在全球呈现快速增长的趋势,2008年流行病学调查显示我国城市人口糖尿病患病率为11%,糖尿病已经成为患者和社会的巨大负担。随着分子生物学、分子免疫学及细胞生物学的发展,干细胞逐渐成为治疗糖尿病及其并发症重要的治疗方法。糖尿病足是糖尿病的慢性并发症之一,是一种危害健康、降低患者生活质量、致残率较高的疾病,传统的药物、血管搭桥、介入手术和截肢术等治疗方法均有局限性。干细胞移植是近年出现的新方法,发展迅速并已应用于临床,其理论基础是干细胞具有分化潜能,可分化成各种机体组织细胞,包括成血管细胞和血管内皮祖细胞(endothelial progenitor cell,EPC),并进一步分化形成新生毛细血管。自体干细胞移植治疗糖尿病足即利用此原理,将干细胞移植到缺血的足部,使其分化形成新生毛细血管,改善局部血流,且无短期不良反应。

In recent years, the prevalence of diabetes shows a rapid growth in the world. In 2008, an epidemiological survey showed that the prevalence of Chinese urban population diabetes was 11%. For patients and society diabetes has become a huge burden. With the development of molecular biology, molecular immunology and cell biology, the stem cells transplantation gradually becomes an important treatment for diabetes and diabetes complications. With a high morbidity, diabetic foot is one of the chronic complications of diabetes, and is a great threat to health and reduces the quality of life. The traditional drugs, surgery, interventional procedures, and amputation treatment all have limitations. As a new method, stem cell transplantation has emerged, which rapidly developed and been used in clinical treatments. The theory behind this is the differentiation potential of stem cells, which can differentiate into a variety of body ceils, including vascular cells and endothelial progenitor cells, and further stem cells can form new capillaries. By this principle, autologous stem cell transplantation was used in the treatment for diabetic foot, the stem cells were transplanted into the ischemic foot. In one hand it can improve theregional blood flow, in the other hand, it has no short-term adverse reaction.